Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Lymphoproliferative Disorders × Trastuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1

Conditions

Breast Neoplasms 4 Stomach Neoplasms 3 HER2-positive Breast Cancer 3 Neoplasms by Site 1 Neoplasms by Histologic Type 1 Neoplasms 1 Lymphoproliferative Disorders 1 Hematologic Neoplasms 1 HER2-positive Gastric Cancer 1 Adenocarcinoma Of Esophagus 1

Interventions

trametinib 1 pertuzumab 1 entrectinib 1 dabrafenib 1 cobimetinib 1 capmatinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Trastuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05722886 2025-11-24

DETERMINE

Cancer Research UK

Phase 2/3 Recruiting

LymphoidOther hematologic neoplasm

Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡